HealthMore in Health→
Chinese CRISPR Therapy Signals a More Competitive Global Gene-Medicine Market
An Endpoints News report says five beta thalassemia patients treated with a Chinese gene-editing therapy no longer need regular transfusions, hinting at rising global competition in genetic medicine.
Key Takeaways
- Endpoints reports that five beta thalassemia patients no longer need regular transfusions after a Chinese CRISPR therapy.
- The result suggests Chinese biotech could become more competitive in genetic medicine.
DE
DT Editorial Team··via endpoints.news